Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00937105 · ClinicalTrials.gov registry record · Phase 4

Daily Wear Corneal Infiltrative Event Study

A Phase 4 study, sponsored by University Hospitals Cleveland Medical Center.

Completed
Registry status
Phase 4
Development phase
218
Enrollment target

NCT00937105: Completed Phase 4 study, sponsored by University Hospitals Cleveland Medical Center.

NCT00937105 is a Phase 4 study that has completed, run by University Hospitals Cleveland Medical Center. The registered enrollment target is 218 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00937105, a Phase 4 study, has completed, sponsored by University Hospitals Cleveland Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
218 participants
Enrollment target

Study Summary

This DWCIE Study is a prospective cohort study of patients fit to the FDA approved and marketed lotrafilcon A (Ciba Vision, Air Optix Night \& Day Aqua) soft contact lenses for daily wear (DW) with monthly disposal. 218 healthy myopic (nearsighted) or hyperopic (farsighted) patients with minimal or no astigmatism and no contraindications to DW lens use will be followed for 1 year. The primary outcome is the risk of development of a corneal inflammatory event (CIE) as defined by slit lamp findings and patient symptoms. The main exposure of interest is microbial contamination of study lenses.

Primary Outcome

Raw number of participants in each solution arm developing CIE over 12 month follow-up period

Interventions

  • DEVICE Clear Care
  • DEVICE lotrafilcon A contact lenses
  • DEVICE Renu Multiplus

Trial Details

FieldValue
Enrollment Target 218 participants
Start Date 2009-11
Est. Completion 2012-02
Phase Phase 4

What the finished NCT00937105 record still lists

NCT00937105 is an interventional study that assigns participants to a tested intervention. The registered 218 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (58% lower).

The record links to 0 conditions, and to 3 interventions - of which Clear Care is the first listed.

NCT00937105 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00937105 about?

NCT00937105 is a clinical study titled "Daily Wear Corneal Infiltrative Event Study". This DWCIE Study is a prospective cohort study of patients fit to the FDA approved and marketed lotrafilcon A (Ciba Vision, Air Optix Night \& Day Aqua) soft contact lenses for daily wear (DW) with monthly disposal. 218 healthy myopic (nearsighted) or hyperopic (farsighted) patients with minimal or ...

What is the current status of trial NCT00937105?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 218 participants. The study started on 2009-11. Estimated completion is 2012-02.

What interventions are being tested in trial NCT00937105?

The interventions under investigation include: Clear Care (DEVICE), lotrafilcon A contact lenses (DEVICE), Renu Multiplus (DEVICE).

Who is sponsoring clinical trial NCT00937105?

This trial is sponsored by University Hospitals Cleveland Medical Center, which has 230 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00937105's enrollment target sits among peer trials

218 390th of 2000 higher than 1,608 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04693858 · 218 participants · NA

    Efficacy Trial of the CALM Intervention

  • NCT05909202 · 218 participants · NA

    A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients

  • NCT06000761 · 218 participants · NA

    Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit

  • NCT06249126 · 218 participants · NA

    Primary Subtalar Arthrodesis for Calcaneal Fractures

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00937105, the US trial registry maintained by the National Library of Medicine. NCT00937105 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.